Akeso Reports Record Sales and Major Oncology Advances in 2025 Interim Results
Akeso's 2025 Interim Results: Commercial Sales Reach New All-Time Highs
On August 26, 2025, Akeso, Inc. (9926.HK) announced remarkable achievements during the first half of 2025, emphasizing a surge in commercial sales and significant advancements in its oncology and autoimmune drug development pipelines. The company's innovative IO 2.0 + ADC 2.0 strategy has been pivotal in cementing its competitive edge in the biopharmaceutical sector.
Key Highlights and Sales Growth
In the first half of 2025, Akeso marked its highest commercial sales to date, with total sales reaching RMB 1,401.6 million, a 49.2% increase compared to RMB 939.4 million in 2024. This impressive growth reflects the company's strategic execution and effective market penetration strategies. With the approval and market introduction of significant treatments such as ivonescimab and cadonilimab, Akeso is addressing critical unmet needs in various cancer types while simultaneously enhancing patient access through inclusion in the National Reimbursement Drug List (NRDL).
Dr. Yu Xia, the founder and CEO of Akeso, expressed gratitude to the company's workforce and partners, acknowledging their contributions to these historic achievements. He emphasized that their
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.